Casey Adams10.01.07
This past July David Graham, MD, a drug safety officer at the FDA called for the withdrawal of Avandia, a leading type 2 diabetes drug marketed by GlaxoSmithKline. Dr. Graham suggested research could indicate the drug possibly caused 205,000 heart attacks and strokes from 1999 to 2006. Dr. Graham also calculated 1600-2200 more patients might suffer these side effects for every month the drug remains on the market. For the over four million type 2 diabetics who've taken the drug since 1999, the announcement was a serious one.
According to the Physician's Desk Reference, rosiglitazone maleate-Avandia's chemical name-increases glycemic control through increased insulin sensitivity. It is considered a PPAR-gamma (peroxisome proliferators-activated receptor-gamma) agonist, modulating genetic expression of insulin sensitivity at the cell membrane.
The multibillion dollar (Avandia's global sales were $3.4 billion last year) question is: What help can nature offer for the estimated 18 million people in the U.S. alone with type 2 non-insulin-dependent diabetes mellitus (NIDDM)-including some 14 million, which have yet to be diagnosed?
In a 2003 review carried out by Harvard Medical School researchers, 108 clinical trials examined no less than 36 different botanicals with potential anti-diabetic properties. Together with another nine trials conducted using supplements, these studies included 4565 diabetic patients. The review concluded that 76% of 58 controlled studies showed improved glucose control1. Many more studies have been added since 2003 as botanical research continues to pile up.
The mechanisms for NIDDM have also undergone vigorous study over the past few years. Primary mechanisms of the past focused on insulin and glucose sensitivity at the cell membrane and the health of pancreatic beta-cells. Recent research has revealed several new complexities.
Originally linked to obesity, leptin is now thought to be involved in hypothalamic energy regulation, stimulation of glucose transport, and the inhibition of insulin secretion by pancreatic beta-cells. Two more recently-discovered hormones are resistin and adiponectin. Resistin has been linked to glucose tolerance and hepatic insulin resistance. Adiponectin is linked to glucose regulation and lipid metabolism. Produced in fat cells, both resistin and adiponectin also apparently mediate PPAR-gamma: resistin upgrades and adiponectin downgrades insulin resistance through PPAR modulation2,3,4.
Enzymes are now thought to be a critical part of the mechanism. One enzyme seemingly instrumental to leptin regulation tangential to PPAR-gamma repression is SIRT1. Sirtuins have been implicated in the diabetic mechanism because of their ability to affect genetic expression related to issues of degenerative glucose and insulin metabolism. SIRT1 appears to balance glucose levels by modulating the PGC-1alpha molecule. PGC-1alpha is a transcriptional co-activator. When SIRT1 was inhibited in vivo this increased hypoglycemia, increased glucose and insulin sensitivity-it also increased free fatty acids and cholesterol. On the other hand, increased SIRT1 expression reversed these effects, but only in the presence of PGC-1alpha during fasting5,6.
Yet another recently discovered hormone implicated in both forms of diabetes is amylin. Amylin is co-secreted with insulin and complements insulin's actions, along with providing a feedback-response mechanism7.
Other components complicating these mechanisms include glucocorticoids and circulating lipids. These various mechanisms compound to make NIDDM associated with stress, hypertension, visceral adiposity, elevated triglycerides, small dense low-density lipoproteins, decreased HDL, and of course, diets high in refined sugars and low in fiber.
A full spectrum strategy for these complex mechanisms is suggested by Virender Sodhi, MD, ND. Dr. Sodhi is also the CEO and co-founder of Ayush Herbs, Inc.-a supplier of Ayurvedic botanical extracts. "I usually suggest to my patients a combination of exercise, multi-herbal therapy and diet modification with plenty of whole food fiber," he says.
Whole foods contain various soluble fibers such as pectin and beta-glucans, which are known to slow glucose absorption rates and bind LDL cholesterol. A 2002 4-week trial of 13 NIDDM men resulted in increased glycemic control, lower plasma glucose and decreased leptin mRNA in high-fiber subjects8.
Oats and Beta-Glucan. Avena sativa L. represents one of the best fiber sources and potent sources of beta-1,3-d-glucan and beta-1,4-d-glucan, as well as avenanthramides-polyphenols shown in studies carried out by Tufts University and USDA's Human Nutrition Center to have potent antioxidant capacity and be LDL-oxidation protective. A Finnish randomized, controlled study of 12 NIDDM patients showed that eating higher beta-glucan oat snacks produced lower glucose fasting and load tolerance levels compared to controls9. The mechanism includes a slowing of digestive enzyme activity and lipid modulation. Other studies have illustrated oat bran's ability to decrease total cholesterol and LDL levels on top of lowered post-meal glucose and insulin10,11.
Several North American suppliers specialize in oat fibers. Cathy Peterson, assistant vice president of applications at SunOpta, Inc., Brampton, Ontario, Canada-a supplier of stabilized oat bran and oat fiber-explains that most of the beta-glucan content of the oat is in the bran. "However the bran also contains a number of enzymes that can create rancidity," she says. For this reason SunOpta stabilizes its bran for use in dry mix applications.
Oat Vantage bran concentrate from GTC Nutrition, Golden, CO, offers up to 54% beta-glucan. ViscoFiber from Cevena Bioproducts, Edmonton, Alberta, Canada, offers a 45% minimum of beta-glucan, with a retention of the bran's natural viscosity and thus many of its health benefits, according to Kristina Williams, Cevena's director of marketing.
Nature can step up the beta-glucan as well. A new variety of high beta-glucan/high avenanthramide oats called HiFi was bred by researchers at North Dakota State University over the past few years. "HiFi is about 50% higher in beta-glucan than the oats you'd buy in the grocery store," says Doug Doehlert, a cereal chemist with the NDSU team. The seed variety has recently entered commercial production under a license agreement between the NDSU Research Foundation and North Dakota's Organic Grain & Milling, Inc. "Hi-Fi is exciting because we've put optimum beta-glucan levels together with an oat giving our organic growers great yields and disease resistance. It's smart science-a real win-win whole grain for farmers and consumers," says Kathryn Begeal, Organic Grain & Milling's director of product development.
Medicinal Mushrooms. Medicinal mushrooms contain beta-1,3-d-glucans with beta-1,6-d-glucan and alpha-1,4-glucans, which contribute to their glycemic and immune function benefits. Mitchell May, PhD, CEO of Utah-based mushroom cultivator Synergy Production Laboratories, points out that in addition to the prized beta-d-glucan, mushrooms contain various enzymes, sterols and triterpenes. "SPL has developed a proprietary and unique cold-drying process that protects these heat-sensitive enzymes," he claims.
Improved insulin sensitivity, increased glucose uptake and binding, insulin-like activity and enhanced immune effects have been shown in a multitude of mushroom studies. "Some of the more researched mushrooms for anti-diabetic action include oyster mushroom, maitake, cordyceps, Tremella fuciformis, Agaricus blazei Murrill, and Jelly Ear fungus Auricularia," according to Brien Quirk, herbalist and R&D development manager, Draco Natural Products, Inc., San Jose, CA. "Of these, maitake seems to have the most research."
David Law, CEO of Gourmet Mushrooms-a 30-year old mushroom cultivating company out of Sebastopol, CA-says his best sellers include C. versicolor, C. sinensis, L. edodes and G. frondosa (maitake). Gourmet Mushrooms currently cultivates 30 different varieties, with another 100 in the spawn bank. He pointed out that while hundreds of mushrooms have glycemic benefits, combination use should include at least one variety of each fungus type-polypores, gilled and jelly varieties.
Mushroom constituents with insulin-like behavior have captured the interest of Merck Research Laboratories, who, after screening upwards of 50,000 compounds, discovered demethylasterriquinone B1 (DAQ) from an African mushroom genus Pseudomassaria. Duke University research team leader Michael Pirrung said DAQ "has this fascinating property of being able to activate insulin receptors in cells in basically the same way as insulin, and yet it's not a protein, as is insulin"12.
Pinus pinaster. An extract from the bark of the French maritime pine tree-a tree indigenous to France-called Pycnogenol has been the subject of more than 200 studies, 50 of which were carried out on humans. "Typical dosage ranged from 20 mg up to 150 mg in the research," said Frank Schonlau, PhD, Natural Health Science's director of scientific communications. Hoboken, NJ-based Natural Health Science represents Pycnogenol in the U.S. In a study reported by the American Diabetes Association's Diabetes Care journal, 30 NIDDM patients took Pycnogenol daily for three weeks. A dosage of 50 mg was enough to significantly lower fasting and postprandial glucose levels-100 mg and 200 mg doses were even more effective13.
The mechanism for Pycnogenol ap-pears to be related to slower glucose uptake, improvement in blood lipids, and increased micro-circulation. The large procyanidin molecules in Pycnogenol inhibit alpha-glucosidase-the enzyme necessary for glucose absorption. Pycnogenol's "side-effect" of increasing micro-circulation was reported helpful for diabetic microangiopathy13.
Fenugreek. Trigonella foenum-graecum is indigenous to West Asia, Southeast Europe and North Africa. It is also cultivated in many other areas. A traditional herb used for glucose control, fenugreek has a long history of success. The crushed plant's seeds contain alkaloids, coumarins and saponins. Its principle active constituent is 4-hydroxyisoleucine. In one study, 17 of 21 NIDDM patients had blood glucose reductions averaging 30 mg/dl after being administered 15 grams of fenugreek as ground seed14.
In another study, 60 NIDDM volunteers reduced fasting blood glucose levels from an average of 151 mg/dl to 112 mg/dl after 24 weeks using a 12.5 mg dosage twice a day15. Other studies have confirmed fenugreek's action of reducing fasting blood sugar levels together with total cholesterol and triglycerides16.
Naturex produces a fenugreek extract standardized to 2% 4-hydroxysoleucine under the name Hydroxylean. Chromatographic column purification allows Naturex to produce fenugreek extracts with up to 80% 4-hydroxysoleucine concentration.
Caiapo. Ipomoea batas or Caiapo is a white sweet potato indigenous to South America that is mostly cultivated in Japan. The high glycoprotein skin of I. batas has exhibited anti-diabetic effects in both animals and humans. In 2002, for example, 18 male NIDDM subjects were treated either with placebo, low (2 grams/day) or high (4 grams/day) doses of caiapo powdered tablets for six weeks. The high-dose group showed 13% reduction in fasting glucose, a 42% increase in insulin sensitivity and a 72% increase in glucose tolerance17,18.
In another study, 61 NIDDM subjects were given either 4 grams of caiapo or placebo daily for 12 weeks. Fasting glucose levels decreased from 143 mg/dl to 128 mg/dl averages in the caiapo group, while remaining unchanged in the placebo group. Two-hour glucose levels were also significantly reduced in the caiapo group19.
Gurmar. Gymnema sylvestre has been in use for thousands of years in Ayurvedic medicine. Its leaves contain gurmarin, gynmenic acids, stigmasterol, quercitol, and various glycosides, resins and saponins. Both the whole plant and its GS4 water-soluble extract fraction have been noted for increased glucose sensitivity and uptake, higher beta-cell count and increased insulin levels. G. sylvestre has been used traditionally for both NIDDM and IDDM (type 1 diabetes). Interestingly, G. sylvestre has the ability to suppress sweet taste stimuli by blocking taste receptors20. This apparently comes from its saponins. Its anti-sweetness effect has been shown to decrease sweet snack consumption21.
G. Sylvestre's diabetic research appears solid. In a 1990 study, 27 insulin-dependent IDDM patients were given 400 grams per day of GS4 over a 10-12 month period. Insulin requirements and glycosylated hemoglobin levels both decreased significantly as compared with control subjects22.
In other smaller studies, G. sylvestre has been shown to have the ability to lower fasting glucose and glycosylated hemoglobin23. In vitro, G. sylvestre also appears to stimulate insulin release by increasing pancreatic beta-cells' membrane permeability24.
Ayush Herbs, Inc. standardizes its G. sylvestre extracts to gymnemic acid content. Shalinder Sodhi, ND, president of Ayush Herbs, suggests a range from 25% to 75% gymnemic acid for efficacy. "We control gurmar production from field through extraction, so we can customize the extraction to specification," he said.
Cinnamon. Cinnamomum cassia shouldn't be confused with "true" Ceylon cinnamon Cinnamomum verum-the variety used for cinnamon sticks. C. cassia is by far more active and also the most used on retail shelves today. C. cassia contains cinnamaldehyde, coumarin, cinnamyl acetate and 2-hydroxycinnamaldehyde25. In vitro analyses reveal that the extract and a water-soluble flavanoid polyphenolic polymer contains insulin-like activity, showing glucose uptake, glycogen synthesis and increased phosphorylation of the insulin receptor26,27,28. Other bioactives have stimulated autophosphorylation of truncated insulin receptors, apparently inhibiting PTP-1-known to shut down the insulin receptor29.
In a 2003 double-blind study of 60 NIDDM volunteers, C. cassia reduced mean fasting serum glucose by 18-29% with significant lipid reductions after 40 days at different dosages30. In a 2006 randomized, double-blind study of 79 NIDDM, subjects took either a water-extracted cinnamon, equivalent to 3 grams, every day for four months or a placebo. Fasting glucose levels fell 10% in the cinnamon group as opposed to only 3% in the placebo group31. Though a 2006 study of postmenopausal NIDDM women curiously showed little effect32, a 2007 study of 14 healthy subjects taking 6 grams of cinnamon in pudding after meals significantly delayed food stomach emptying and reduced postprandial glucose levels33.
Cinnamon happens to be Draco's biggest anti-diabetes seller. "Draco uses a proprietary pressurized hot-water extraction process that breaks down the plant cell walls to yield an 8% flavanoid standardization," Mr. Quirk said.
Garcinia Cambogia. The rind of this small fruit grown in Asia contains hydroxycitric acid (HCA), which has undergone several human and in vivo studies showing appetite reduction, increased fat oxidation, lower triglycerides, reductions in body weight34, substantially decreased leptin levels35, and more recently, lower fasting glucose levels36.
A patented HCA extract from InterHealth Nutraceuticals, Inc., Benecia, CA, was the subject of the latter two studies. "Our Super CitriMax has been shown to provide numerous benefits that can help those who are risk for or suffer from type 2 diabetes, including benefits related to weight-management and cardiovascular health," said Paul Dijkstra, InterHealth Nutraceuticals' CEO.
Bitter Melon. Mormordica charantia is another traditional botanical used in the area of diabetes. Constituents charantin, vincin and polypeptide-p from the juice of the unripe fruit have been reported to have anti-diabetic activity. Though still subject to debate, the mechanisms for bitter melon appear to be related to polypeptide-p's insulin-like behavior, along with glucose absorption inhibition, regulation/
stimulation of insulin and improved glycogen-synthesis. Despite limited human studies, several in vivo studies have shown bitter melon to have a 30% to 48% lowering effect on blood glucose levels37,38,39,40,41.
Ayush's Dr. V. Sodhi says M. charantia's long history of clinical use in India is due to its dual-mechanism: "While synthetic drugs typically have one mechanism, botanical genetics more closely match the complicated nature of human genetics. Botanicals thus have a dual effect of upgrading or downgrading activity as needed to balance a particular weakness," he said.
Prickly pear cactus. Opuntia streptacantha and Opuntia ficus indicaenus-also referred to as nopal-grow primarily in the arid climates of Mexico and the Southwestern U.S. In reviewing the literature on both human and animal studies, it appears that nopal's glucose tolerance effects appear to stem from its ability to modulate LDL cholesterol42. Various clinical trials done in Spain with NIDDM patients concluded that nopal reduced serum glucose levels following dextrose challenges43,44,45,46,47.
Coccina indica. C. indica is a creeper growing primarily in India and Bangladesh. Extracts from the roots and leaves are used in anti-diabetic preparations. C. indica appears to be significantly high in pectins, chitooligosaccharide-specific lectin and a number of other components. In a 1998 study, 500 mg/kg body weight of dried extract was given to 30 NIDDM patients for six weeks. Increased-glucose control was concluded. From the data it appeared that C. indica's insulin-like activity was related to modulating several glyolytic and lipolytic enzymes and the repression of the glucose-6-phosphatase enzyme48.
In a six-week trial of 32 NIDDM patients, 10 of 16 patients taking C. indica showed significant improvement in glucose tolerance, while none in the control group showed improvement49. A number of in vivo studies have also shown C. indica's ability to lower fasting glucose levels, some as low as 24%50.
Aloe vera. The dried gel from the Aloe vera plant (family:Aloeaceae) has been shown useful in three studies on NIDDM. Five phytosterols, lophenol, 24-methyl-lophenol, 24-ethyl-lophenol, cycloartanol, and 24-methylene-cycloartanol, together with the water-soluble fiber glucomannan, appear to be the active constituents. Blood sugar reduction of up to 55% has been shown in in vivo research51. The mechanism is thought to be related to its beta-cell protective effects, inhibitory effects on glucose-absorption speed and a modulation of liver enzymes.
A half-teaspoonful of aloe daily for four to 14 weeks decreased fasting glucose levels from a mean of 273 mg/dl to 151 mg/dl for five NIDDM patients52. Two other human studies have confirmed similar effects with one teaspoon daily53,54.
Naturex' aloe extract called Verapure standardizes to 5% aloe polysaccharides using a nuclear magnetic resonance assay. Antoine Dauby, marketing manager at Naturex, says the polysaccharide concentration can be changed to spec.
Pterocarpus marsupium. Perhaps one of the most illustrative studies showing botanicals' NIDDM effects was published in 2005. In a double-blind, randomized study comparing Pterocarpus marsupium with the popular diabetes drug tolbutamide, 365 newly-diagnosed or untreated NIDDM patients were treated either with P. marsupium or tobutamide for 36 weeks. Eighty-six percent of the Pterocarpus treatment group achieved glycemic control, while 94% of the 177 tolbutamide-treated patients achieved control, based on fasting and postprandial blood glucose (with average reduction ranges of 23-31% and 28%-34%, respectively). As other trials of this botanical have confirmed, there were no adverse effects in the Pterocarpus group55.
Dr. Shalinder Sodhi discussed Pterocarpus in more detail. "It has a very long history of use in India for both types of diabetes," he said. "The entire bark of the tree can be used as a powder or whole piece. In India it is sometimes administered as a cup carved from the tree wood, with the prescription being to fill the cup with water, let it soak overnight to absorb the extract, and drink the water the next day. The bioactive constituents will no longer be present when the color of the flavanoid disappears from the water." The mechanism for Pterocarpus-with constituents thought to be epicatechin, marsupin and pterosupin-is not well understood, but Dr. Sodhi says it is believed to restore beta-cell health.
Other Botanical Options. There are several lesser-known botanicals showing blood-sugar metabolism effects. In fact, Draco's Mr. Quirk claims there is a long list of extracts with limited research showing beneficial blood sugar management effects, including Solomon seal, Eucommia, Rehmannia, plum extract, miracle fruit (Synsepalum dulcificum), litchi fruit, cornus fruit (cornelian cherry or dogwood fruit), goji berry, black rice extract, stevia and Lo Han Guo (Siraitia grosvenori)." He goes on to say that spice extracts from the Labiatae family-including sage, oregano, rosemary, and lemon balm-work by inhibiting alpha glucosidase. "Astragalus sp. and Rhodiola crenulata also have unappreciated research showing anti-diabetic activity," he said.
Ayush's Dr. Sodhi attests to the range of botanical options, adding neem (Azadirachta indica) as one of the more underrated botanicals with anti-diabetic action. Last year a study of 10 NIDDM patients showed neem's significant hypoglycemic effects56. Still, Dr. Sodhi says, "There are so many traditional botanicals that support glycemic function in one way or another."
Thus it appears this is only the tip of the iceberg when it comes to the potential for botanical solutions in blood sugar disorders. FDA drug safety officer Dr. Graham will probably appreciate this as he considers botanical medicine's long safety history.
References
1. Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003 26(4):1277-1294.
2. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA.The hormone resistin links obesity to diabetes. Nature. 2001; Jan 18;409(6818):307-12.
3. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; May;86(5):1930-5.
4. Chatterjee V. PPAR gamma and human insulin resistance. Endocrine Abstracts 2 SP6: Society for Endrocrinology. 2001; Dec; Society for Endrocrinology.
5. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA. 2007 Jul 31;104(31):12861-6.
6. Das UN. A defect in the activity of Delta6 and Delta5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prost-aglandins Leukot Essent Fatty Acids. 2005; May;72(5):343-50.
7. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001; Sep;7(14):1353-73.
8. Kabir M, Oppert JM, Vidal H, Bruzzo F, Fiquet C, Wursch P, Slama G, Rizkalla SW. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Metabolism. 2002; Jul;51(7):819-26.
9. Tapola N, Karvonen H, Niskanen L, Mikola M, Sarkkinen E. Glycemic responses of oat bran products in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2005; Aug;15(4):255-61.
10. Pick ME, Hawrysh ZJ, Gee MI, Toth E, Garg ML, Hardin RT. Oat bran concentrate bread products improve long-term control of diabetes: a pilot study. J Am Diet Assoc. 1996; Dec;96(12):1254-61.
11. Reyna NY, Cano C, Bermudez VJ, Medina MT, Souki AJ, Ambard M, Nunez M, Ferrer MA, Inglett GE. Sweeteners and beta-glucans improve metabolic and anthropometrics variables in well controlled type 2 diabetic patients. Am J Ther. 2003; Nov-Dec;10(6):438-43.
12. Basqall M. Synthetic Fungal Compound Could Lead to Oral Diabetes Drug. Science & Engineering News. Duke Research Magazine. 2001; Apr.
13. Liu X et al. French maritime pine bark extract Pycnogenol dose-dependently lowers glucose in type II diabetes patients. Diabetes Care. 2004; 27:839.
14. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr. 1988; 42:51-54.
15. Sharma RD, Sarkar A, Hazra DK. Use of fenugreek seed powder in the management of non-inslin dependent diabetes mellitus. Nutr Res. 1996; 16:1331-1339.
16. Shapiro K, Gong WC. Natural products used for diabetes. J Am Pharm Assoc (Wash). 2002; 42:217-226.
17. Ludvik BH, Mahdjoobian K, Waldhaeusl W et al. The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized study. Diabetes Care. 2002; 25:239-240.
18. Ludvik B, Waldhausl W, Prager R, Kautzky-Willer A, Pacini G. Mode of action of Ipomoea batatas (Caiapo) in type 2 diabetic patients. Metabolism. 2003; 52:875-880.
19. Ludvik B, Neuffer B, Pacini G. Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet. Diabetes Care. 2004; 27:436-440.
20. Min BC, Sakamoto K. Influence of sweet suppressing agent on gustatory brain evoked potentials generated by taste stimuli. Appl Human Sci. 1998; Jan;17(1):9-17.
21. Brala PM, Hagen RL. Effects of sweetness perception and caloric value of a preload on short term intake. Physiol Behav. 1983; Jan;30(1):1-9.
22. Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol. 1990; Oct;30(3):281-94.
23. Shapiro K, Gong WC. Natural products used for diabetes. J Am Pharm Assoc (Wash). 2002; Mar-Apr;42(2):217-26.
24. Persaud SJ, Al-Majed H, Raman A, Jones PM. Gymnema sylvestre stimulates insulin release in vitro by increased membrane permeability. Journal of Endocrinology, Vol 163, Issue 2, 207-212
25. Choi J, Lee KT, Ka H, Jung WT, Jung HJ, Park HJ. Constituents of the essential oil of the Cinnamomum cassia stem bark and the biological properties. Arch Pharm Res. 2001; Oct;24(5):418-23.
26. Berrio LF, Polansky MM, Anderson RA. Insulin activity: stimulatory effects of cinnamon and brewer's yeast as influenced by albumin. Horm Res. 1992; 37:225-229.
27. Imparl-Radosevich J, Deas S, Polansky MM, Baedke DA, Ingebrutsen TS, Anderson RA, Graves DJ: Regulation of phosphorylase phosphatase (PTP-1) and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signaling. Horm Res. 1998; 50:177182.
28. Jarvill-Taylor KJ, Anderson RA, Graves DJ: A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3L1 adipocytes. J Am Coll Nutr. 2001; 20:327336.
29. Evans JL, Jallal B. Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Exp Opin Invest Drugs. 1999; 8:139-160.
30. Khan A, Safdar M, li Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003; 26:3215-3218.
31. Mang B, Wolters M, Schmitt B et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest. 2006; 36:340-344.
32. Vanschoonbeek K, Thomassen BJ, Senden JM, Wodzig WK, van Loon LJ. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr. 2006. Apr; 136(4):977-80.
33. Hlebowicz J, Darwiche G, Bjorgell O, Almer LO. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J Clin Nutr. 2007 Jun;85(6):1552-6.
34. Downs BW, Bagchi M, Subbaraju GV, Shara MA, Preuss HG, Bagchi D. Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid. Mutat Res. 2005 Nov 11;579(1-2):149-62.
35. Preuss HG, Bagchi D, Bagchi M, Rao CV, Dey DK, Satyanarayana S. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obes Metab. 2004 May;6(3):171-80. AND Preuss HG, Garis RI, Bramble JD, Bagchi D, Bagchi M, Rao CV, Satyanarayana S. Efficacy of a novel calcium/potassium salt of (-)-hydroxycitric acid in weight control. Int J Clin Pharmacol Res. 2005;25(3):133-44.
36. Asghar M, Monjok E, Kouamou G, Ohia SE, Bagchi D, Lokhandwala MF. Super CitriMax (HCA-SX) attenuates increases in oxidative stress, inflammation, insulin resistance, and body weight in developing obese Zucker rats. Mol Cell Biochem. 2007 May 15.
37. Shetty AK, Kumar GS, Sambaiah K, Salimath PV. Effect of bitter gourd (Momordica charantia) on glycemic status in streptozotocin induced diabetic rats. Plant Foods Hum Nutr. 2005 Sep;60(3):109-12.
38. Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK. Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol. 2003 Sep;88(1):107-11.
39. Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR, Suzuki I. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol (Tokyo). 2001 Oct;47(5):340-4.
40. Miura T, Itoh Y, Iwamoto N, Kato M, Ishida T. Suppressive activity of the fruit of Momordica charantia with exercise on blood glucose in type 2 diabetic mice. Biol Pharm Bull. 2004 Feb;27(2):248-50.
41. Vikrant V, Grover JK, Tandon N, Rathi SS, Gupta N. Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J Ethnopharmacol. 2001 Jul;76(2):139-43.
42. Cardenas Medellin ML, Serna Saldivar SO, Velazco de la Garza J. Effect of raw and cooked nopal (Opuntia ficus indica) ingestion on growth and profile of total cholesterol, lipoproteins, and blood glucose in rats. Arch Latinoam Nutr. 1998 Dec;48(4):316-23.
43. Frati Munari AC, Vera Lastra O, Ariza Andraca CR. Evaluation of nopal capsules in diabetes mellitus. Gac Med Mex. 1992 Jul-Aug;128(4):431-6.
44. Frati-Munari AC, Roca-Vides RA, Lopez-Perez RJ, de Vivero I, Ruiz-Velazco M. The glycemic index of some foods common in Mexico. Gac Med Mex. 1991 Mar-Apr;127(2):163-70; discussion 170-1.
45. Frati-Munari AC, de Leon C, Ariza-Andraca R, Banales-Ham MB, Lopez-Ledesma R, Lozoya X. Effect of a dehydrated extract of nopal (Opuntia ficus indica Mill.) on blood glucose. Arch Invest Med (Mex). 1989 Jul-Sep;20(3):211-6.
46. Frati-Munari AC, Del Valle-Martinez LM, Ariza-Andraca CR, Islas-Andrade S, Chavez-Negrete A. Hypoglycemic action of different doses of nopal (Opuntia streptacantha Lemaire) in patients with type II diabetes mellitus. Arch Invest Med (Mex). 1989 Apr-Jun;20(2):197-201.
47. Frati-Munari AC, Gordillo BE, Altamirano P, Ariza CR. Hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM. Diabetes Care. 1988 Jan;11(1):63-6.
48. Kamble SM, Kamlakar PL, Vaidya S, Bambole VD. Influence of Coccinia indica on certain enzymes in glycolytic and lipolytic pathway in human diabetes. Indian J Med Sci. 1998 Apr;52(4):143-6.
49. Azad Khan AK, Akhtar S, Mahtab H. Coccinia indica in the treatment of patients with diabetes mellitus. Bangladesh Med Res Counc Bull. 1979 Dec;5(2):60-6.
50. Hossain MZ, Shibib BA, Rahman R. Hypoglycemic effects of Coccinia indica: inhibition of key gluconeogenic enzyme, glucose-6-phosphatase. Indian J Exp Biol. 1992 May;30(5):418-20.
51. Tanaka M, Misawa E, Ito Y, Habara N, Nomaguchi K, Yamada M, Toida T, Hayasawa, H, Takase M, Inagaki M, Higuchi R. Identification of five phytosterols from Aloe vera gel as anti-diabetic compounds. Biol Pharm Bull. 2006 Jul;29(7):1418-22.
52. Ghannam N, Kingston M, Al Meshaal IA, Tariq M, Parman NS, Woodhouse N. The antidiabetic activity of aloes: preliminary clinical and experimental observations. Horm Res. 1986; 24:288-294.
53. Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice: I. Clinical trial in new cases of diabetes mellitus. Phytomed. 1996; 3:241-243.
54. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice: II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. Phytomed. 1996; 3:245-248.
55. Hariharan R.S. et al. (ICMR Study Group on Efficacy of Vijayasar in Type 2 Diabetes Mellitus.) Efficacy of Vijayasar (Pterocarpus Marsupium) in the treatment of newly diagnosed patients with type 2 diabetes mellitus: A flexible dose double-blind multicenter randomized controlled trial. Diabetol. Croat. 2005:34-1:May,pp13-19.
56. Waheed A, Miana GA, Ahmad SI. Clinical investigation of hypoglycemic effect of seeds of Azadirachta-inidca in type-2 (NIDDM) diabetes mellitus. Pak J Pharm Sci. 2006 Oct;19(4):322-5.
According to the Physician's Desk Reference, rosiglitazone maleate-Avandia's chemical name-increases glycemic control through increased insulin sensitivity. It is considered a PPAR-gamma (peroxisome proliferators-activated receptor-gamma) agonist, modulating genetic expression of insulin sensitivity at the cell membrane.
The multibillion dollar (Avandia's global sales were $3.4 billion last year) question is: What help can nature offer for the estimated 18 million people in the U.S. alone with type 2 non-insulin-dependent diabetes mellitus (NIDDM)-including some 14 million, which have yet to be diagnosed?
In a 2003 review carried out by Harvard Medical School researchers, 108 clinical trials examined no less than 36 different botanicals with potential anti-diabetic properties. Together with another nine trials conducted using supplements, these studies included 4565 diabetic patients. The review concluded that 76% of 58 controlled studies showed improved glucose control1. Many more studies have been added since 2003 as botanical research continues to pile up.
New Mechanisms Found
The mechanisms for NIDDM have also undergone vigorous study over the past few years. Primary mechanisms of the past focused on insulin and glucose sensitivity at the cell membrane and the health of pancreatic beta-cells. Recent research has revealed several new complexities.
Originally linked to obesity, leptin is now thought to be involved in hypothalamic energy regulation, stimulation of glucose transport, and the inhibition of insulin secretion by pancreatic beta-cells. Two more recently-discovered hormones are resistin and adiponectin. Resistin has been linked to glucose tolerance and hepatic insulin resistance. Adiponectin is linked to glucose regulation and lipid metabolism. Produced in fat cells, both resistin and adiponectin also apparently mediate PPAR-gamma: resistin upgrades and adiponectin downgrades insulin resistance through PPAR modulation2,3,4.
Enzymes are now thought to be a critical part of the mechanism. One enzyme seemingly instrumental to leptin regulation tangential to PPAR-gamma repression is SIRT1. Sirtuins have been implicated in the diabetic mechanism because of their ability to affect genetic expression related to issues of degenerative glucose and insulin metabolism. SIRT1 appears to balance glucose levels by modulating the PGC-1alpha molecule. PGC-1alpha is a transcriptional co-activator. When SIRT1 was inhibited in vivo this increased hypoglycemia, increased glucose and insulin sensitivity-it also increased free fatty acids and cholesterol. On the other hand, increased SIRT1 expression reversed these effects, but only in the presence of PGC-1alpha during fasting5,6.
Yet another recently discovered hormone implicated in both forms of diabetes is amylin. Amylin is co-secreted with insulin and complements insulin's actions, along with providing a feedback-response mechanism7.
Other components complicating these mechanisms include glucocorticoids and circulating lipids. These various mechanisms compound to make NIDDM associated with stress, hypertension, visceral adiposity, elevated triglycerides, small dense low-density lipoproteins, decreased HDL, and of course, diets high in refined sugars and low in fiber.
Full-Spectrum Strategy
A full spectrum strategy for these complex mechanisms is suggested by Virender Sodhi, MD, ND. Dr. Sodhi is also the CEO and co-founder of Ayush Herbs, Inc.-a supplier of Ayurvedic botanical extracts. "I usually suggest to my patients a combination of exercise, multi-herbal therapy and diet modification with plenty of whole food fiber," he says.
Whole foods contain various soluble fibers such as pectin and beta-glucans, which are known to slow glucose absorption rates and bind LDL cholesterol. A 2002 4-week trial of 13 NIDDM men resulted in increased glycemic control, lower plasma glucose and decreased leptin mRNA in high-fiber subjects8.
Oats and Beta-Glucan. Avena sativa L. represents one of the best fiber sources and potent sources of beta-1,3-d-glucan and beta-1,4-d-glucan, as well as avenanthramides-polyphenols shown in studies carried out by Tufts University and USDA's Human Nutrition Center to have potent antioxidant capacity and be LDL-oxidation protective. A Finnish randomized, controlled study of 12 NIDDM patients showed that eating higher beta-glucan oat snacks produced lower glucose fasting and load tolerance levels compared to controls9. The mechanism includes a slowing of digestive enzyme activity and lipid modulation. Other studies have illustrated oat bran's ability to decrease total cholesterol and LDL levels on top of lowered post-meal glucose and insulin10,11.
Several North American suppliers specialize in oat fibers. Cathy Peterson, assistant vice president of applications at SunOpta, Inc., Brampton, Ontario, Canada-a supplier of stabilized oat bran and oat fiber-explains that most of the beta-glucan content of the oat is in the bran. "However the bran also contains a number of enzymes that can create rancidity," she says. For this reason SunOpta stabilizes its bran for use in dry mix applications.
Oat Vantage bran concentrate from GTC Nutrition, Golden, CO, offers up to 54% beta-glucan. ViscoFiber from Cevena Bioproducts, Edmonton, Alberta, Canada, offers a 45% minimum of beta-glucan, with a retention of the bran's natural viscosity and thus many of its health benefits, according to Kristina Williams, Cevena's director of marketing.
Nature can step up the beta-glucan as well. A new variety of high beta-glucan/high avenanthramide oats called HiFi was bred by researchers at North Dakota State University over the past few years. "HiFi is about 50% higher in beta-glucan than the oats you'd buy in the grocery store," says Doug Doehlert, a cereal chemist with the NDSU team. The seed variety has recently entered commercial production under a license agreement between the NDSU Research Foundation and North Dakota's Organic Grain & Milling, Inc. "Hi-Fi is exciting because we've put optimum beta-glucan levels together with an oat giving our organic growers great yields and disease resistance. It's smart science-a real win-win whole grain for farmers and consumers," says Kathryn Begeal, Organic Grain & Milling's director of product development.
Medicinal Mushrooms. Medicinal mushrooms contain beta-1,3-d-glucans with beta-1,6-d-glucan and alpha-1,4-glucans, which contribute to their glycemic and immune function benefits. Mitchell May, PhD, CEO of Utah-based mushroom cultivator Synergy Production Laboratories, points out that in addition to the prized beta-d-glucan, mushrooms contain various enzymes, sterols and triterpenes. "SPL has developed a proprietary and unique cold-drying process that protects these heat-sensitive enzymes," he claims.
Improved insulin sensitivity, increased glucose uptake and binding, insulin-like activity and enhanced immune effects have been shown in a multitude of mushroom studies. "Some of the more researched mushrooms for anti-diabetic action include oyster mushroom, maitake, cordyceps, Tremella fuciformis, Agaricus blazei Murrill, and Jelly Ear fungus Auricularia," according to Brien Quirk, herbalist and R&D development manager, Draco Natural Products, Inc., San Jose, CA. "Of these, maitake seems to have the most research."
David Law, CEO of Gourmet Mushrooms-a 30-year old mushroom cultivating company out of Sebastopol, CA-says his best sellers include C. versicolor, C. sinensis, L. edodes and G. frondosa (maitake). Gourmet Mushrooms currently cultivates 30 different varieties, with another 100 in the spawn bank. He pointed out that while hundreds of mushrooms have glycemic benefits, combination use should include at least one variety of each fungus type-polypores, gilled and jelly varieties.
Mushroom constituents with insulin-like behavior have captured the interest of Merck Research Laboratories, who, after screening upwards of 50,000 compounds, discovered demethylasterriquinone B1 (DAQ) from an African mushroom genus Pseudomassaria. Duke University research team leader Michael Pirrung said DAQ "has this fascinating property of being able to activate insulin receptors in cells in basically the same way as insulin, and yet it's not a protein, as is insulin"12.
Pinus pinaster. An extract from the bark of the French maritime pine tree-a tree indigenous to France-called Pycnogenol has been the subject of more than 200 studies, 50 of which were carried out on humans. "Typical dosage ranged from 20 mg up to 150 mg in the research," said Frank Schonlau, PhD, Natural Health Science's director of scientific communications. Hoboken, NJ-based Natural Health Science represents Pycnogenol in the U.S. In a study reported by the American Diabetes Association's Diabetes Care journal, 30 NIDDM patients took Pycnogenol daily for three weeks. A dosage of 50 mg was enough to significantly lower fasting and postprandial glucose levels-100 mg and 200 mg doses were even more effective13.
The mechanism for Pycnogenol ap-pears to be related to slower glucose uptake, improvement in blood lipids, and increased micro-circulation. The large procyanidin molecules in Pycnogenol inhibit alpha-glucosidase-the enzyme necessary for glucose absorption. Pycnogenol's "side-effect" of increasing micro-circulation was reported helpful for diabetic microangiopathy13.
Fenugreek. Trigonella foenum-graecum is indigenous to West Asia, Southeast Europe and North Africa. It is also cultivated in many other areas. A traditional herb used for glucose control, fenugreek has a long history of success. The crushed plant's seeds contain alkaloids, coumarins and saponins. Its principle active constituent is 4-hydroxyisoleucine. In one study, 17 of 21 NIDDM patients had blood glucose reductions averaging 30 mg/dl after being administered 15 grams of fenugreek as ground seed14.
In another study, 60 NIDDM volunteers reduced fasting blood glucose levels from an average of 151 mg/dl to 112 mg/dl after 24 weeks using a 12.5 mg dosage twice a day15. Other studies have confirmed fenugreek's action of reducing fasting blood sugar levels together with total cholesterol and triglycerides16.
Naturex produces a fenugreek extract standardized to 2% 4-hydroxysoleucine under the name Hydroxylean. Chromatographic column purification allows Naturex to produce fenugreek extracts with up to 80% 4-hydroxysoleucine concentration.
Caiapo. Ipomoea batas or Caiapo is a white sweet potato indigenous to South America that is mostly cultivated in Japan. The high glycoprotein skin of I. batas has exhibited anti-diabetic effects in both animals and humans. In 2002, for example, 18 male NIDDM subjects were treated either with placebo, low (2 grams/day) or high (4 grams/day) doses of caiapo powdered tablets for six weeks. The high-dose group showed 13% reduction in fasting glucose, a 42% increase in insulin sensitivity and a 72% increase in glucose tolerance17,18.
In another study, 61 NIDDM subjects were given either 4 grams of caiapo or placebo daily for 12 weeks. Fasting glucose levels decreased from 143 mg/dl to 128 mg/dl averages in the caiapo group, while remaining unchanged in the placebo group. Two-hour glucose levels were also significantly reduced in the caiapo group19.
Gurmar. Gymnema sylvestre has been in use for thousands of years in Ayurvedic medicine. Its leaves contain gurmarin, gynmenic acids, stigmasterol, quercitol, and various glycosides, resins and saponins. Both the whole plant and its GS4 water-soluble extract fraction have been noted for increased glucose sensitivity and uptake, higher beta-cell count and increased insulin levels. G. sylvestre has been used traditionally for both NIDDM and IDDM (type 1 diabetes). Interestingly, G. sylvestre has the ability to suppress sweet taste stimuli by blocking taste receptors20. This apparently comes from its saponins. Its anti-sweetness effect has been shown to decrease sweet snack consumption21.
G. Sylvestre's diabetic research appears solid. In a 1990 study, 27 insulin-dependent IDDM patients were given 400 grams per day of GS4 over a 10-12 month period. Insulin requirements and glycosylated hemoglobin levels both decreased significantly as compared with control subjects22.
In other smaller studies, G. sylvestre has been shown to have the ability to lower fasting glucose and glycosylated hemoglobin23. In vitro, G. sylvestre also appears to stimulate insulin release by increasing pancreatic beta-cells' membrane permeability24.
Ayush Herbs, Inc. standardizes its G. sylvestre extracts to gymnemic acid content. Shalinder Sodhi, ND, president of Ayush Herbs, suggests a range from 25% to 75% gymnemic acid for efficacy. "We control gurmar production from field through extraction, so we can customize the extraction to specification," he said.
Cinnamon. Cinnamomum cassia shouldn't be confused with "true" Ceylon cinnamon Cinnamomum verum-the variety used for cinnamon sticks. C. cassia is by far more active and also the most used on retail shelves today. C. cassia contains cinnamaldehyde, coumarin, cinnamyl acetate and 2-hydroxycinnamaldehyde25. In vitro analyses reveal that the extract and a water-soluble flavanoid polyphenolic polymer contains insulin-like activity, showing glucose uptake, glycogen synthesis and increased phosphorylation of the insulin receptor26,27,28. Other bioactives have stimulated autophosphorylation of truncated insulin receptors, apparently inhibiting PTP-1-known to shut down the insulin receptor29.
In a 2003 double-blind study of 60 NIDDM volunteers, C. cassia reduced mean fasting serum glucose by 18-29% with significant lipid reductions after 40 days at different dosages30. In a 2006 randomized, double-blind study of 79 NIDDM, subjects took either a water-extracted cinnamon, equivalent to 3 grams, every day for four months or a placebo. Fasting glucose levels fell 10% in the cinnamon group as opposed to only 3% in the placebo group31. Though a 2006 study of postmenopausal NIDDM women curiously showed little effect32, a 2007 study of 14 healthy subjects taking 6 grams of cinnamon in pudding after meals significantly delayed food stomach emptying and reduced postprandial glucose levels33.
Cinnamon happens to be Draco's biggest anti-diabetes seller. "Draco uses a proprietary pressurized hot-water extraction process that breaks down the plant cell walls to yield an 8% flavanoid standardization," Mr. Quirk said.
Garcinia Cambogia. The rind of this small fruit grown in Asia contains hydroxycitric acid (HCA), which has undergone several human and in vivo studies showing appetite reduction, increased fat oxidation, lower triglycerides, reductions in body weight34, substantially decreased leptin levels35, and more recently, lower fasting glucose levels36.
A patented HCA extract from InterHealth Nutraceuticals, Inc., Benecia, CA, was the subject of the latter two studies. "Our Super CitriMax has been shown to provide numerous benefits that can help those who are risk for or suffer from type 2 diabetes, including benefits related to weight-management and cardiovascular health," said Paul Dijkstra, InterHealth Nutraceuticals' CEO.
Bitter Melon. Mormordica charantia is another traditional botanical used in the area of diabetes. Constituents charantin, vincin and polypeptide-p from the juice of the unripe fruit have been reported to have anti-diabetic activity. Though still subject to debate, the mechanisms for bitter melon appear to be related to polypeptide-p's insulin-like behavior, along with glucose absorption inhibition, regulation/
stimulation of insulin and improved glycogen-synthesis. Despite limited human studies, several in vivo studies have shown bitter melon to have a 30% to 48% lowering effect on blood glucose levels37,38,39,40,41.
Ayush's Dr. V. Sodhi says M. charantia's long history of clinical use in India is due to its dual-mechanism: "While synthetic drugs typically have one mechanism, botanical genetics more closely match the complicated nature of human genetics. Botanicals thus have a dual effect of upgrading or downgrading activity as needed to balance a particular weakness," he said.
Prickly pear cactus. Opuntia streptacantha and Opuntia ficus indicaenus-also referred to as nopal-grow primarily in the arid climates of Mexico and the Southwestern U.S. In reviewing the literature on both human and animal studies, it appears that nopal's glucose tolerance effects appear to stem from its ability to modulate LDL cholesterol42. Various clinical trials done in Spain with NIDDM patients concluded that nopal reduced serum glucose levels following dextrose challenges43,44,45,46,47.
Coccina indica. C. indica is a creeper growing primarily in India and Bangladesh. Extracts from the roots and leaves are used in anti-diabetic preparations. C. indica appears to be significantly high in pectins, chitooligosaccharide-specific lectin and a number of other components. In a 1998 study, 500 mg/kg body weight of dried extract was given to 30 NIDDM patients for six weeks. Increased-glucose control was concluded. From the data it appeared that C. indica's insulin-like activity was related to modulating several glyolytic and lipolytic enzymes and the repression of the glucose-6-phosphatase enzyme48.
In a six-week trial of 32 NIDDM patients, 10 of 16 patients taking C. indica showed significant improvement in glucose tolerance, while none in the control group showed improvement49. A number of in vivo studies have also shown C. indica's ability to lower fasting glucose levels, some as low as 24%50.
Aloe vera. The dried gel from the Aloe vera plant (family:Aloeaceae) has been shown useful in three studies on NIDDM. Five phytosterols, lophenol, 24-methyl-lophenol, 24-ethyl-lophenol, cycloartanol, and 24-methylene-cycloartanol, together with the water-soluble fiber glucomannan, appear to be the active constituents. Blood sugar reduction of up to 55% has been shown in in vivo research51. The mechanism is thought to be related to its beta-cell protective effects, inhibitory effects on glucose-absorption speed and a modulation of liver enzymes.
A half-teaspoonful of aloe daily for four to 14 weeks decreased fasting glucose levels from a mean of 273 mg/dl to 151 mg/dl for five NIDDM patients52. Two other human studies have confirmed similar effects with one teaspoon daily53,54.
Naturex' aloe extract called Verapure standardizes to 5% aloe polysaccharides using a nuclear magnetic resonance assay. Antoine Dauby, marketing manager at Naturex, says the polysaccharide concentration can be changed to spec.
Pterocarpus marsupium. Perhaps one of the most illustrative studies showing botanicals' NIDDM effects was published in 2005. In a double-blind, randomized study comparing Pterocarpus marsupium with the popular diabetes drug tolbutamide, 365 newly-diagnosed or untreated NIDDM patients were treated either with P. marsupium or tobutamide for 36 weeks. Eighty-six percent of the Pterocarpus treatment group achieved glycemic control, while 94% of the 177 tolbutamide-treated patients achieved control, based on fasting and postprandial blood glucose (with average reduction ranges of 23-31% and 28%-34%, respectively). As other trials of this botanical have confirmed, there were no adverse effects in the Pterocarpus group55.
Dr. Shalinder Sodhi discussed Pterocarpus in more detail. "It has a very long history of use in India for both types of diabetes," he said. "The entire bark of the tree can be used as a powder or whole piece. In India it is sometimes administered as a cup carved from the tree wood, with the prescription being to fill the cup with water, let it soak overnight to absorb the extract, and drink the water the next day. The bioactive constituents will no longer be present when the color of the flavanoid disappears from the water." The mechanism for Pterocarpus-with constituents thought to be epicatechin, marsupin and pterosupin-is not well understood, but Dr. Sodhi says it is believed to restore beta-cell health.
Other Botanical Options. There are several lesser-known botanicals showing blood-sugar metabolism effects. In fact, Draco's Mr. Quirk claims there is a long list of extracts with limited research showing beneficial blood sugar management effects, including Solomon seal, Eucommia, Rehmannia, plum extract, miracle fruit (Synsepalum dulcificum), litchi fruit, cornus fruit (cornelian cherry or dogwood fruit), goji berry, black rice extract, stevia and Lo Han Guo (Siraitia grosvenori)." He goes on to say that spice extracts from the Labiatae family-including sage, oregano, rosemary, and lemon balm-work by inhibiting alpha glucosidase. "Astragalus sp. and Rhodiola crenulata also have unappreciated research showing anti-diabetic activity," he said.
Ayush's Dr. Sodhi attests to the range of botanical options, adding neem (Azadirachta indica) as one of the more underrated botanicals with anti-diabetic action. Last year a study of 10 NIDDM patients showed neem's significant hypoglycemic effects56. Still, Dr. Sodhi says, "There are so many traditional botanicals that support glycemic function in one way or another."
Thus it appears this is only the tip of the iceberg when it comes to the potential for botanical solutions in blood sugar disorders. FDA drug safety officer Dr. Graham will probably appreciate this as he considers botanical medicine's long safety history.
About the author: Casey Adams, DSc, holds a Doctor of Sciences in Integrative Health, is board certified as an Alternative Medical Practitioner and practices at the Wellness and Rehabilitation Center in Watsonville, CA. He can be reached at cadams@realnaturalhealth.com.
References
1. Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003 26(4):1277-1294.
2. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA.The hormone resistin links obesity to diabetes. Nature. 2001; Jan 18;409(6818):307-12.
3. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; May;86(5):1930-5.
4. Chatterjee V. PPAR gamma and human insulin resistance. Endocrine Abstracts 2 SP6: Society for Endrocrinology. 2001; Dec; Society for Endrocrinology.
5. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA. 2007 Jul 31;104(31):12861-6.
6. Das UN. A defect in the activity of Delta6 and Delta5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prost-aglandins Leukot Essent Fatty Acids. 2005; May;72(5):343-50.
7. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001; Sep;7(14):1353-73.
8. Kabir M, Oppert JM, Vidal H, Bruzzo F, Fiquet C, Wursch P, Slama G, Rizkalla SW. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Metabolism. 2002; Jul;51(7):819-26.
9. Tapola N, Karvonen H, Niskanen L, Mikola M, Sarkkinen E. Glycemic responses of oat bran products in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2005; Aug;15(4):255-61.
10. Pick ME, Hawrysh ZJ, Gee MI, Toth E, Garg ML, Hardin RT. Oat bran concentrate bread products improve long-term control of diabetes: a pilot study. J Am Diet Assoc. 1996; Dec;96(12):1254-61.
11. Reyna NY, Cano C, Bermudez VJ, Medina MT, Souki AJ, Ambard M, Nunez M, Ferrer MA, Inglett GE. Sweeteners and beta-glucans improve metabolic and anthropometrics variables in well controlled type 2 diabetic patients. Am J Ther. 2003; Nov-Dec;10(6):438-43.
12. Basqall M. Synthetic Fungal Compound Could Lead to Oral Diabetes Drug. Science & Engineering News. Duke Research Magazine. 2001; Apr.
13. Liu X et al. French maritime pine bark extract Pycnogenol dose-dependently lowers glucose in type II diabetes patients. Diabetes Care. 2004; 27:839.
14. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr. 1988; 42:51-54.
15. Sharma RD, Sarkar A, Hazra DK. Use of fenugreek seed powder in the management of non-inslin dependent diabetes mellitus. Nutr Res. 1996; 16:1331-1339.
16. Shapiro K, Gong WC. Natural products used for diabetes. J Am Pharm Assoc (Wash). 2002; 42:217-226.
17. Ludvik BH, Mahdjoobian K, Waldhaeusl W et al. The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized study. Diabetes Care. 2002; 25:239-240.
18. Ludvik B, Waldhausl W, Prager R, Kautzky-Willer A, Pacini G. Mode of action of Ipomoea batatas (Caiapo) in type 2 diabetic patients. Metabolism. 2003; 52:875-880.
19. Ludvik B, Neuffer B, Pacini G. Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet. Diabetes Care. 2004; 27:436-440.
20. Min BC, Sakamoto K. Influence of sweet suppressing agent on gustatory brain evoked potentials generated by taste stimuli. Appl Human Sci. 1998; Jan;17(1):9-17.
21. Brala PM, Hagen RL. Effects of sweetness perception and caloric value of a preload on short term intake. Physiol Behav. 1983; Jan;30(1):1-9.
22. Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol. 1990; Oct;30(3):281-94.
23. Shapiro K, Gong WC. Natural products used for diabetes. J Am Pharm Assoc (Wash). 2002; Mar-Apr;42(2):217-26.
24. Persaud SJ, Al-Majed H, Raman A, Jones PM. Gymnema sylvestre stimulates insulin release in vitro by increased membrane permeability. Journal of Endocrinology, Vol 163, Issue 2, 207-212
25. Choi J, Lee KT, Ka H, Jung WT, Jung HJ, Park HJ. Constituents of the essential oil of the Cinnamomum cassia stem bark and the biological properties. Arch Pharm Res. 2001; Oct;24(5):418-23.
26. Berrio LF, Polansky MM, Anderson RA. Insulin activity: stimulatory effects of cinnamon and brewer's yeast as influenced by albumin. Horm Res. 1992; 37:225-229.
27. Imparl-Radosevich J, Deas S, Polansky MM, Baedke DA, Ingebrutsen TS, Anderson RA, Graves DJ: Regulation of phosphorylase phosphatase (PTP-1) and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signaling. Horm Res. 1998; 50:177182.
28. Jarvill-Taylor KJ, Anderson RA, Graves DJ: A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3L1 adipocytes. J Am Coll Nutr. 2001; 20:327336.
29. Evans JL, Jallal B. Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Exp Opin Invest Drugs. 1999; 8:139-160.
30. Khan A, Safdar M, li Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003; 26:3215-3218.
31. Mang B, Wolters M, Schmitt B et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest. 2006; 36:340-344.
32. Vanschoonbeek K, Thomassen BJ, Senden JM, Wodzig WK, van Loon LJ. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr. 2006. Apr; 136(4):977-80.
33. Hlebowicz J, Darwiche G, Bjorgell O, Almer LO. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J Clin Nutr. 2007 Jun;85(6):1552-6.
34. Downs BW, Bagchi M, Subbaraju GV, Shara MA, Preuss HG, Bagchi D. Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid. Mutat Res. 2005 Nov 11;579(1-2):149-62.
35. Preuss HG, Bagchi D, Bagchi M, Rao CV, Dey DK, Satyanarayana S. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obes Metab. 2004 May;6(3):171-80. AND Preuss HG, Garis RI, Bramble JD, Bagchi D, Bagchi M, Rao CV, Satyanarayana S. Efficacy of a novel calcium/potassium salt of (-)-hydroxycitric acid in weight control. Int J Clin Pharmacol Res. 2005;25(3):133-44.
36. Asghar M, Monjok E, Kouamou G, Ohia SE, Bagchi D, Lokhandwala MF. Super CitriMax (HCA-SX) attenuates increases in oxidative stress, inflammation, insulin resistance, and body weight in developing obese Zucker rats. Mol Cell Biochem. 2007 May 15.
37. Shetty AK, Kumar GS, Sambaiah K, Salimath PV. Effect of bitter gourd (Momordica charantia) on glycemic status in streptozotocin induced diabetic rats. Plant Foods Hum Nutr. 2005 Sep;60(3):109-12.
38. Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK. Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol. 2003 Sep;88(1):107-11.
39. Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR, Suzuki I. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol (Tokyo). 2001 Oct;47(5):340-4.
40. Miura T, Itoh Y, Iwamoto N, Kato M, Ishida T. Suppressive activity of the fruit of Momordica charantia with exercise on blood glucose in type 2 diabetic mice. Biol Pharm Bull. 2004 Feb;27(2):248-50.
41. Vikrant V, Grover JK, Tandon N, Rathi SS, Gupta N. Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J Ethnopharmacol. 2001 Jul;76(2):139-43.
42. Cardenas Medellin ML, Serna Saldivar SO, Velazco de la Garza J. Effect of raw and cooked nopal (Opuntia ficus indica) ingestion on growth and profile of total cholesterol, lipoproteins, and blood glucose in rats. Arch Latinoam Nutr. 1998 Dec;48(4):316-23.
43. Frati Munari AC, Vera Lastra O, Ariza Andraca CR. Evaluation of nopal capsules in diabetes mellitus. Gac Med Mex. 1992 Jul-Aug;128(4):431-6.
44. Frati-Munari AC, Roca-Vides RA, Lopez-Perez RJ, de Vivero I, Ruiz-Velazco M. The glycemic index of some foods common in Mexico. Gac Med Mex. 1991 Mar-Apr;127(2):163-70; discussion 170-1.
45. Frati-Munari AC, de Leon C, Ariza-Andraca R, Banales-Ham MB, Lopez-Ledesma R, Lozoya X. Effect of a dehydrated extract of nopal (Opuntia ficus indica Mill.) on blood glucose. Arch Invest Med (Mex). 1989 Jul-Sep;20(3):211-6.
46. Frati-Munari AC, Del Valle-Martinez LM, Ariza-Andraca CR, Islas-Andrade S, Chavez-Negrete A. Hypoglycemic action of different doses of nopal (Opuntia streptacantha Lemaire) in patients with type II diabetes mellitus. Arch Invest Med (Mex). 1989 Apr-Jun;20(2):197-201.
47. Frati-Munari AC, Gordillo BE, Altamirano P, Ariza CR. Hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM. Diabetes Care. 1988 Jan;11(1):63-6.
48. Kamble SM, Kamlakar PL, Vaidya S, Bambole VD. Influence of Coccinia indica on certain enzymes in glycolytic and lipolytic pathway in human diabetes. Indian J Med Sci. 1998 Apr;52(4):143-6.
49. Azad Khan AK, Akhtar S, Mahtab H. Coccinia indica in the treatment of patients with diabetes mellitus. Bangladesh Med Res Counc Bull. 1979 Dec;5(2):60-6.
50. Hossain MZ, Shibib BA, Rahman R. Hypoglycemic effects of Coccinia indica: inhibition of key gluconeogenic enzyme, glucose-6-phosphatase. Indian J Exp Biol. 1992 May;30(5):418-20.
51. Tanaka M, Misawa E, Ito Y, Habara N, Nomaguchi K, Yamada M, Toida T, Hayasawa, H, Takase M, Inagaki M, Higuchi R. Identification of five phytosterols from Aloe vera gel as anti-diabetic compounds. Biol Pharm Bull. 2006 Jul;29(7):1418-22.
52. Ghannam N, Kingston M, Al Meshaal IA, Tariq M, Parman NS, Woodhouse N. The antidiabetic activity of aloes: preliminary clinical and experimental observations. Horm Res. 1986; 24:288-294.
53. Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice: I. Clinical trial in new cases of diabetes mellitus. Phytomed. 1996; 3:241-243.
54. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice: II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. Phytomed. 1996; 3:245-248.
55. Hariharan R.S. et al. (ICMR Study Group on Efficacy of Vijayasar in Type 2 Diabetes Mellitus.) Efficacy of Vijayasar (Pterocarpus Marsupium) in the treatment of newly diagnosed patients with type 2 diabetes mellitus: A flexible dose double-blind multicenter randomized controlled trial. Diabetol. Croat. 2005:34-1:May,pp13-19.
56. Waheed A, Miana GA, Ahmad SI. Clinical investigation of hypoglycemic effect of seeds of Azadirachta-inidca in type-2 (NIDDM) diabetes mellitus. Pak J Pharm Sci. 2006 Oct;19(4):322-5.